COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT00343642
Previous Study | Return to List | Next Study

Dietary Treatment of Crohn's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00343642
Recruitment Status : Completed
First Posted : June 23, 2006
Last Update Posted : January 28, 2014
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Rush University Medical Center

Brief Summary:
Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.

Condition or disease Intervention/treatment Phase
Crohn's Disease Inflammatory Bowel Disease Dietary Supplement: Time and attention + fructo-oligosaccharide placebo Dietary Supplement: dietary therapy + fructo-oligosaccharide placebo Drug: Time and attention + active fructooligosaccharide supplementation Phase 1 Phase 2

Detailed Description:

Several epidemiological studies and therapeutic observations in the complementary and alternative medicine (CAM) literature suggest that diet is key to development of CD and its treatment. The investigators took advantage of these CAM recommendations and designed dietary interventions. Our preliminary open label studies in IBD patients showed that our interventions are acceptable and well-tolerated and result in improvement, reducing symptoms and/or the degree of inflammation. The investigators are now seeking to validate this finding and determine the mechanisms underlying the effects of dietary manipulation-such as potential effects on colonic bacterial microflora. In another pilot study using 16s rDNA bacterial fingerprinting, the investigators demonstrated that the intestinal microflora of patients with CD differ significantly from healthy individuals. Whether the investigators can normalize/change the microflora of CD patients with dietary therapies, however, remains to be determined. Accordingly, the investigators designed a double blind placebo controlled study to test the hypotheses that: (1) dietary manipulation with either diet or a FOS supplement is an effective CAM therapy that prevents CD relapse (leads to maintenance of remission) and (2) such dietary manipulation can normalize the microflora of CD patients and decrease mucosal oxidative damage.

90 participants are expected to undergo the trial and have a 2:1 chance of receiving active therapy. The trial is seeking to enroll participants with inactive CD who have been medically induced into remission within 9 months of enrollment. Participants must be on their Crohn's medications at a stable dose for 3 months, which does not include steroids (e.g. Prednisone, Entocort) or antibiotics at the time of enrollment. Participants will be followed till relapse occurs or up to 52 weeks. Participants are asked to fill out a variety of questionnaires, keep a food and adverse event diary, and have a research, limited, unprepped flexible sigmoidoscopy for colonic tissue collection at the beginning and end of the study period.

Significance. This study could provide information to suggest diet or dietary supplement as a safe therapy for IBD and lay the groundwork for more definitive, randomized, controlled trials.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Dietary Treatment of Crohn's Disease
Study Start Date : September 2006
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Placebo Comparator: 1
Time and attention + fructooligosaccharide placebo
Dietary Supplement: Time and attention + fructo-oligosaccharide placebo
2 teaspoons of placebo powder daily

Active Comparator: 2
Dietary therapy + fructooligosaccharide placebo
Dietary Supplement: dietary therapy + fructo-oligosaccharide placebo
Medical nutrition therapy and 2 teaspoons of placebo powder

Experimental: 3
Time and attention + active fructooligosaccharide supplement.
Drug: Time and attention + active fructooligosaccharide supplementation
2 teaspoons of fructooligosaccharides daily

Primary Outcome Measures :
  1. Efficacy of dietary treatment in maintaining remission of Crohn's disease [ Time Frame: 90 days ]
  2. Quality of life in patients taking dietary treatments [ Time Frame: 90 days ]
  3. Safety of dietary treatments [ Time Frame: 90 days ]

Secondary Outcome Measures :
  1. Utility of dietary treatments for patients [ Time Frame: 90 days ]
  2. Changes in ileocolonic flora [ Time Frame: 90 days ]
  3. Changes in colonic oxidative stress [ Time Frame: 90 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Documented ileocolonic or colonic CD based on classical history and classical endoscopic or surgical findings and histology compatible with CD;
  2. Induction of remission with medical therapy within 9 months of the study;
  3. Inactive CD for at least 2 weeks with CDAI score less than 150;
  4. No change in IBD medication doses for 3 months;
  5. No change in smoking habits a month prior to enrollment (because smoking may exacerbate CD) and acceptance of not-changing smoking habits during the term of the study).

Exclusion Criteria:

  1. Patients with history of bowel obstruction and/or known strictures (as the high fiber content may precipitate obstruction);
  2. Patients with extensive colonic or ileocolonic resection;
  3. Patients with ileostomies or colostomies with diverted fecal stream;
  4. Patients with isolated perianal/anorectal disease;
  5. Patients with surgically induced remission;
  6. Concomitant infection (e.g., C. difficile colitis);
  7. Use of antibiotics within 4 weeks, or steroids, herbal remedies or diet therapies within 2 weeks of the onset of the trial or during the study;
  8. Use of potential IBD exacerbators such as NSAIDs within 1 wk of the study;
  9. Acute illness requiring immediate hospitalization for CD or other reasons;
  10. Presence of symptomatic organic GI disease other than CD, hemorrhoids, hiatal hernia; GERD;
  11. Pre-existent organ failure or severe comorbidities as these may change Gl flora:

    • Liver disease (cirrhosis or persistently abnormal AST or ALT that are 2X> normal);
    • Kidney disease (creatinine>2.0 mg/dL);
    • Uncontrolled psychiatric illness;
    • Clinically important lung disease or heart failure;
    • HIV disease;
    • Alcoholism;
    • Transplant recipients;
    • Patients receiving other immunosuppressant medications for comorbidities (e.g. Enbrel for rheumatoid arthritis);
  12. Presence of short bowel syndrome or severe malnutrition with ideal body weight less than or equal to 90% or predicted;
  13. Estimated survival <1 year and Karnofsky performance status <50%;
  14. Desire to become pregnant during study or current pregnancy or nursing;
  15. Desire to change smoking-status during the study;
  16. Daily use of anticoagulation and antiplatelet medications;
  17. Complicated IBD with anticipation of imminent surgical intervention during the term of the study;
  18. Inability to have a regular follow-up and comply with study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00343642

Layout table for location information
United States, Georgia
Gastroenterology Associates of Central Georgia
Macon, Georgia, United States, 31201
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
National Center for Complementary and Integrative Health (NCCIH)
Layout table for investigator information
Principal Investigator: Ece A Mutlu, MD MBA Rush University Medical Center
Study Director: Ali Keshavarzian, MD Rush University Medical Center
Study Director: Shahriar Sedghi, MD Gastroenterology Associates of Central Georgia
Layout table for additonal information
Responsible Party: Rush University Medical Center Identifier: NCT00343642    
Other Study ID Numbers: R21AT001628-01A2 ( U.S. NIH Grant/Contract )
R21AT001628-01A2 ( U.S. NIH Grant/Contract )
First Posted: June 23, 2006    Key Record Dates
Last Update Posted: January 28, 2014
Last Verified: January 2014
Keywords provided by Rush University Medical Center:
Crohn's disease
Bacterial flora
Oxidative stress
Additional relevant MeSH terms:
Layout table for MeSH terms
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases